Sugi Predict

Sugi Predict / Compounds / SCHEMBL7033933

SCHEMBL7033933

SCHEMBL7033933

Cn1c(=O)[nH]c(=O)c2c1ncn2CC1CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ MAPK1 P28482 2/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ PMP22 Q01453 1/20 0.57
▸ KDM4E B2RXH2 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ POLB P06746 1/20 0.55
▸ PDE4A P27815 4/20 0.50
▸ ADORA2A P29274 4/20 0.50
▸ PDE4B Q07343 4/20 0.50
▸ PDE4C Q08493 4/20 0.50
▸ PDE4D Q08499 4/20 0.50
▸ KMT2A Q03164 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ BRD4 O60885 4/20 0.47
▸ BRD2 P25440 2/20 0.47
▸ BRD3 Q15059 2/20 0.47
▸ BRDT Q58F21 2/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15931519 0.95 SMN1; SMN2 (0.55) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL17314818 0.95 SMN1; SMN2 (0.55) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL18256061 0.95 SMN1; SMN2 (0.57) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL18256051 0.95 SMN1; SMN2 (0.57) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL17314877 0.94 SMN1; SMN2 (0.54) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL17314878 0.94 SMN1; SMN2 (0.54) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL18256135 0.93 SMN1; SMN2 (0.56) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL15923932 0.91 SMN1; SMN2 (0.54) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL17314452 0.91 SMN1; SMN2 (0.51) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E
SCHEMBL17314451 0.91 SMN1; SMN2 (0.51) SMN1; SMN2MAPK1CYP3A4PMP22KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111233863-B Hydroxyl purine compound and application thereof 广东众生睿创生物科技有限公司 2022-10-25 — — CN disclosed
US-RE49128-E1 Hydroxyl purine compounds and applications thereof Guangdong Raynovent Biotech Co., Ltd. (CN) 2022-07-12 — — US disclosed
US-RE49128-E1 Hydroxyl purine compounds and applications thereof Guangdong Raynovent Biotech Co., Ltd. (CN) 2022-07-12 — — US disclosed
EP-3205652-B1 HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) 2022-03-09 — — EP disclosed
CN-108348525-B Medical application of hydroxyl purine compound 广东众生睿创生物科技有限公司 2021-09-10 — — CN disclosed
CN-111233863-A Hydroxyl purine compound and application thereof 广东众生睿创生物科技有限公司 2020-06-05 — — CN disclosed
US-10618898-B2 Hydroxyl purine compounds and use thereof Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-04-14 — — US disclosed
CN-105566324-B Hydroxyl purine compound and application thereof 广东众生睿创生物科技有限公司 2020-04-03 — — CN disclosed
CN-107614501-B Hydroxyl purine compound and application thereof 广东众生睿创生物科技有限公司 2020-01-14 — — CN disclosed
US-10399981-B2 Crystal form A of 7-(cyclopropylmethyl)-1-(((cis )-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-09-03 — — US disclosed
WO-2016184312-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF 南京明德新药研发股份有限公司 2016-11-24 — — WO disclosed
WO-2016184313-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF 南京明德新药研发股份有限公司 2016-11-24 — — WO disclosed
WO-2016054971-A1 HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF 南京明德新药研发股份有限公司 2016-04-14 — — WO disclosed
EP-0797448-B1 COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE HOECHST AG (DE) 2003-02-26 — — EP disclosed
CN-1096859-C Combination preparation, containing cyclosporin a or FK506 or rapamycin and a xanthine derivative HOECHST AG (DE) 2002-12-25 — — CN disclosed
US-6432968-B1 IMMUNOSUPPRESSANTS FOR PATIENTS WITH CANCER, AUTOIMMUNE DISEASES, AND VIRAL INFECTIONS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-08-13 — — US disclosed
US-6046328-A Combination preparation, containing cyclosporin A or FK506 or rapamycin and a xanthine derivative AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-04-04 — — US disclosed
CN-1162919-A Combination preparation, containing cyclosporin a or FK506 or rapamycin and a xanthine derivative HOECHST AG (DE) 1997-10-22 — — CN disclosed
EP-0797448-A2 COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE HOECHST AKTIENGESELLSCHAFT (DE) 1997-10-01 — — EP disclosed
WO-1996005854-A2 COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE HOECHST AKTIENGESELLSCHAFT (DE) 1996-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10618898-B2 Hydroxyl purine compounds and use thereof PNP, PDE7A, PDE2A SMN1; SMN2 1801/4885MAPK1 931/4885CYP3A4 487/4885
US-10399981-B2 Crystal form A of 7-(cyclopropylmethyl)-1-(((cis )-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases PDE2A, PDE7A, PDE7B SMN1; SMN2 3523/4885MAPK1 958/4885CYP3A4 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.